Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

医学 布仑妥昔单抗维多汀 达卡巴嗪 内科学 ABVD公司 无容量 肿瘤科 长春碱 化疗方案 淋巴瘤 博莱霉素 化疗 外科 癌症 霍奇金淋巴瘤 长春新碱 环磷酰胺 免疫疗法
作者
Bruce D. Cheson,Nancy L. Bartlett,Betsy LaPlant,Hun Ju Lee,Ranjana H. Advani,Beth Christian,Catherine Diefenbach,Tatyana Feldman,Stephen M. Ansell
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:7 (11): e808-e815 被引量:89
标识
DOI:10.1016/s2352-3026(20)30275-1
摘要

Summary

Background

Hodgkin lymphoma is potentially curable. However, 15–35% of older patients (ie, >60 years) have a lower response rate, worse survival outcomes, and greater toxicity than younger patients. Brentuximab vedotin and nivolumab exhibit activity in patients with relapsed or refractory Hodgkin lymphoma. We therefore aimed to evaluate the safety and efficacy of brentuximab vedotin and nivolumab in untreated older patients with Hodgkin lymphoma or in younger patients considered unsuitable for standard ABVD (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy.

Methods

We did a multicentre, single-arm, phase 2 trial at eight cancer centres in the USA. Previously untreated patients with classic Hodgkin lymphoma were eligible for study enrolment if they were 60 years or older, or younger than 60 years but considered unsuitable for standard chemotherapy because of a cardiac ejection fraction of less than 50%, pulmonary diffusion capacity of less than 80%, or a creatinine clearance of 30 mL/min or more but less than 60 mL/min, or those who refused chemotherapy. Patients were also required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Patients received brentuximab vedotin at 1·8 mg/kg (dose cap at 180 mg) and nivolumab at 3 mg/kg both intravenously every 21 days for 8 cycles. The primary endpoint was the overall response, defined as a partial metabolic response or complete metabolic response at the end of 8 cycles of treatment. A per protocol analysis was done including all patients who received treatment in the activity and safety analyses. This study is registered with ClinicalTrials.gov, number NCT02758717.

Findings

Between May 13, 2016, and Jan 30, 2019, the study accrued 46 patients. The median age was 71·5 years (IQR 64–77), with two (4%) of 46 patients younger than 60 years. Median follow-up was 21·2 months (IQR 15·6–29·9), and 35 (76%) of 46 patients completed all 8 cycles of therapy. At the interim analysis on Oct 11, 2019, the first 25 evaluable patients had an overall response rate of 64% ([95% CI 43–82] 16 of 25 patients; 13 [52%] had a complete metabolic response and three [12%] had a partial metabolic response). The trial was closed to accrual on Oct 14, 2019, after the interim analysis failed to meet the predefined criteria. In all 46 evaluable patients, 22 (48%) patients achieved a complete metabolic response and six (13%) achieved a partial metabolic response (overall response rate 61% [95% CI 45–75]). 14 (30%) of 46 patients had 16 dose adjustments, primarily due to neurotoxicity. 22 (48%) of 46 patients had peripheral neuropathy (five [11%] patients had grade 3 peripheral neuropathy). Grade 4 adverse events included increased aminotranferases (one [2%] of 46), increased lipase or amylase (two [4%]), and pancreatitis (one [2%]). One (2%) patient died from cardiac arrest, possibly treatment related.

Interpretation

Although the trial did not meet the prespecified activity criteria, brentuximab vedotin plus nivolumab is active in older patients with previously untreated Hodgkin lymphoma with comorbidities. The regimen was also well tolerated in the majority of patients in this older population. Future trials should be based on optimising the dose and schedule, perhaps combined with other targeted agents that might permit chemotherapy-free strategies in older patients with Hodgkin lymphoma.

Funding

Seattle Genetics and Bristol Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
可爱紫文完成签到 ,获得积分0
刚刚
令狐觅双发布了新的文献求助10
1秒前
奋斗蚂蚁完成签到 ,获得积分10
2秒前
lily完成签到,获得积分20
2秒前
Akim的应助被风吹麦浪采纳,获得10
3秒前
ddd发布了新的文献求助10
4秒前
4秒前
4秒前
Mobius发布了新的文献求助10
5秒前
lily发布了新的文献求助10
5秒前
初度发布了新的文献求助10
6秒前
ranqiang完成签到,获得积分20
7秒前
winner完成签到,获得积分10
7秒前
8秒前
8秒前
SciGPT的应助被斯文雪青采纳,获得10
8秒前
8秒前
9秒前
昏睡的翩跹关注了科研通微信公众号
9秒前
科研通AI6.4的应助被苹果绿采纳,获得10
10秒前
忧郁人英完成签到,获得积分10
10秒前
huahuahua发布了新的文献求助10
11秒前
洛必达完成签到,获得积分10
11秒前
小花发布了新的文献求助50
12秒前
12秒前
12秒前
科目三的应助被winner采纳,获得10
13秒前
14秒前
kdxjlm发布了新的文献求助10
14秒前
luff关注了科研通微信公众号
14秒前
beyondfar发布了新的文献求助10
14秒前
李健的应助被WYL采纳,获得10
14秒前
kunnao完成签到,获得积分10
15秒前
令狐觅双完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
风趣的惠发布了新的文献求助10
16秒前
泥泥完成签到 ,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190887
求助须知:如何正确求助?哪些是违规求助? 9577962
关于积分的说明 21855797
捐赠科研通 7790040
什么是DOI,文献DOI怎么找? 3436475
关于科研通互助平台的介绍 2560312
邀请新用户注册赠送积分活动 2483216